152 related articles for article (PubMed ID: 32176062)
41. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
42. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
43. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.
Chang CY; Huang SP; Chiu HM; Lee YC; Chen MF; Lin JT
Hepatogastroenterology; 2006; 53(67):1-4. PubMed ID: 16506366
[TBL] [Abstract][Full Text] [Related]
44. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
45. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
46. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
47. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
[TBL] [Abstract][Full Text] [Related]
48. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
49. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
50. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
51. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
52. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
53. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.
Molina V; Visa L; Conill C; Navarro S; Escudero JM; Auge JM; Filella X; Lopez-Boado MA; Ferrer J; Fernandez-Cruz L; Molina R
Tumour Biol; 2012 Jun; 33(3):799-807. PubMed ID: 22203495
[TBL] [Abstract][Full Text] [Related]
54. Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology.
Jin XL; Xu B; Wu YL
World J Gastroenterol; 2014 Oct; 20(40):14958-64. PubMed ID: 25356057
[TBL] [Abstract][Full Text] [Related]
55. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
56. Prognostic values of normal preoperative serum cancer markers for gastric cancer.
Feng F; Sun L; Liu Z; Liu S; Zheng G; Xu G; Guo M; Lian X; Fan D; Zhang H
Oncotarget; 2016 Sep; 7(36):58459-58469. PubMed ID: 27533455
[TBL] [Abstract][Full Text] [Related]
57. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
58. Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder.
Bind MK; Mishra RR; Kumar V; Misra V; Singh PA
Indian J Pathol Microbiol; 2021; 64(1):65-68. PubMed ID: 33433411
[TBL] [Abstract][Full Text] [Related]
59. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
60. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Knox JJ; McNamara MG; Jitlal M; Wasan H; Bridgewater J; Valle JW; Mau-Sorensen M
Eur J Cancer; 2015 Jul; 51(11):1381-8. PubMed ID: 25971532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]